lexiara

preamble_13

(3) in the European Union, only limited action has been taken so far, whether at national or at Community level, to stimulate the development of orphan medicinal products; such action is best taken at Community level in order to take advantage of the widest possible market and to avoid the dispersion of limited resources; action at Community level is preferable to uncoordinated measures by the Member States which may result in distortions of competition and barriers to intra-Community trade;

· All articles ·

Source: EUR-Lex (Cellar) · retrieved 2026-11-21 · Text as adopted (Official Journal); later amendments are not incorporated in this text.